The QualityStocks Daily Tuesday, August 2nd, 2022

Today's Top 3 Investment Newsletters

MarketClub Analysis(MTC) $7.8500 +390.63%

QualityStocks(APDN) $2.8000 +311.16%

ChineseWire(IFBD) $0.4600 +23.49%

The QualityStocks Daily Stock List

MMTec (MTC)

StreetInsider, StockMarketWatch, QualityStocks, TradersPro, Stockhouse and BUYINS.NET reported earlier on MMTec (MTC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MMTec Inc. (NASDAQ: MTC) is a firm that is engaged in asset management services on various platforms. The firm has its headquarters in Beijing in the People’s Republic of China and was founded in 2015.

The firm provides solutions in securities settlements, market transactions and internet-based technology services to brokerage firms, mutual and hedge funds, proprietary trading groups and registered investment advisors worldwide. MMTec’s operating segments are MM Global and Gujia. The firm generates the majority of its revenue from the Gujia segment, which provides investor relations management and market data services to consumers in China.

MMTec Inc. is mainly involved in offering complete suite trading solutions, which include settlement and trading, distribution, custody and fund creation services, all of which assist financial institutions in boosting their integration into markets abroad. It also allows its consumers to select modular functionalities and white label its trading interface.

The firm’s platforms include the quantitative investment transaction platform, ETN counter business system, institutional and personal integrated account management systems, PC transaction client systems for Web, Android, PC and Apple IOS, personal mobile trading client system and PTN private fund investment management systems, which support requisition management, multi-account management, liquidation, fund valuation, risk management and quantitative trading access.

MMTec Inc. is near the top firms in its industry group, ranking at 74 in the Software Application Industry with its involvement in cryptocurrency moving the company higher up. Companies involved in the “currency of the future” may reap big benefits, particularly because the world is moving further into the digital realm, which will require more use of digital currencies.

MMTec (MTC), closed Tuesday's trading session at $7.85, up 390.625%, on 13,109,485 volume. The average volume for the last 3 months is 13.109M and the stock's 52-week low/high is $1.41/$17.50.

Fangdd Network Group (DUO)

StocksEarning, QualityStocks, StreetInsider, StockMarketWatch and MarketBeat reported earlier on Fangdd Network Group (DUO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fangdd Network Group Ltd. (NASDAQ: DUO) is an investment holding firm that is engaged in the provision of real estate services and solutions for real estate brokers via real estate trading platforms that can be accessed online.

The firm has its headquarters in Shenzhen, the People’s Republic of China and was incorporated in 2011. It operates in the real estate sector, under the real estate services sub-industry and serves consumers in China. The firm generates most of its revenue from Base commission from transactions in China.

The enterprise operates a platform for real estate agents known as Duoduo sales, which allows them to access primary listings, a huge real estate buyer base and marketplace services and products like premium marketplace functions, data analytic tools, shared listings and artificial-intelligence based marketplace assistance. The enterprise’s other platform Fangduoduo provides secondary and primary listings, pricing information services, real estate market news and vacation properties.

The company also provides a core management system which allows agents and agencies to carry out their daily operations, like cooperating with participants in other marketplaces, serving real estate buyers and manage listings; and also offers online shops which allow agents to engage with, connect and/or reach real estate sellers and buyers, which integrates their offline and online operations with its ranking, agent verification and management systems.

The firm has more than a million real estate agents in China on its platform, the total number being slightly more than 2 million. As more agents join and use its platforms, its reach will be extended which will in turn bring in more investors.

Fangdd Network Group (DUO), closed Tuesday's trading session at $3.4, up 61.9048%, on 1,945,632 volume. The average volume for the last 3 months is 1.791M and the stock's 52-week low/high is $1.61/$28.80.

Boqii Holding Ltd (BQ)

StreetInsider, StocksEarning, QualityStocks, MarketClub Analysis, MarketBeat and InvestorPlace reported earlier on Boqii Holding Ltd (BQ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Boqii Holding Ltd (NYSE: BQ) is a holding firm that operates a pet-focused platform. The firm has its headquarters in Shanghai, the People’s Republic of China and was incorporated in December 2007 by Chen Di, Tang Yingzhi and Liang Hai. It mainly serves consumers in China.

The company mainly operates through its subsidiaries and sells its products through online and offline channels, to pet hospitals and stores. It also owns an online platform known as Boqii Mall through which it sells its pet products under the Mocare and Yoken brands. The company has an interactive and informative content platform dubbed Boqii Community which enables users to discover new ways and products that can make their pets happier and healthier as well as share their pet parenting experiences.

The enterprise offers services through its subsidiaries. It is primarily engaged in the sale of pet-related products like pet foods and accessories, which includes oxygen pumps, temperature control equipment, aquatic fertilizer, fish tanks, pet toys, pet bathing products, pet grooming products, health products and pet foods. This is in addition to offering animal care services. Additionally, the enterprise is involved in online information and marketing services place and business advertisements for brand owners.

The company recently announced its latest financial results for this fiscal year which show an increase in total revenues and decrease in net loss. It is focused on expanding and optimizing its portfolio offerings, in addition to being committed to bringing in more buyers while retaining the existing buyers.

Boqii Holding Ltd (BQ), closed Tuesday's trading session at $2.69, up 58.2353%, on 1,051,828 volume. The average volume for the last 3 months is 980,471 and the stock's 52-week low/high is $1.3338/$18.78.

Applied DNA Sciences (APDN)

Greenbackers, OTCPicks, QualityStocks, MarketClub Analysis, Free Hot Penny Stocks, StockMarketWatch, MarketBeat, Penny Stock Pick Alert, IRGnews Alert, Wall Street Resources, BUYINS.NET, The PennyStock Picks, Early Bird, Real Pennies, Standout Stocks, SuperNova Elite, Super Nova Stock Picks, TraderPower, StreetInsider, We Pick Penny Stocks, Liquid Tycoon, Stock Analyzer, Penny Stock MoneyTrain, StockEgg, Beacon Equity Research, FeedBlitz, Super Hot Penny Stocks, OTCReporter, MicroStockProfit, HotOTC, CoolPennyStocks, Schaeffer's, Trades Of The Day, Wall Street Grand, Penny Stock Finder, PennyTrader Publisher, Proactivecrg, Penny Stock Solutions, Top Stock Picks, Penny Stock Pick Report, Investor Ideas, HotPennyStocksNow, Penny Stock Chaser, Penny Pick Finders, Penny Performers, Micro Cap Pulse, Otcstockexchange, BullRally, Lebed.biz, Marketbeat.com, InvestorPlace, Dubai Penny Stocks, INO.com Market Report, OTCtipReporter, PennyStockCrowd, SmallCapVoice, Profitable Trader Authority, The Penny Play, StockOnion, Stock Rich, PennyStockScholar, PennyStockProphet, PennyStockVille, TradersPro, StockHideout, PennyInvest, Stockpalooza, Penny stock-pick, 24-7 Stock Alert, PennyStocks24, StockRich, ThePUMPTracker, StockRun, Streetwise Reports, HEROSTOCKS, DrStockPick, Daily Trade Alert, Top Stock Tips, Buzz Stocks, Trading Concepts and BoonMarket reported earlier on Applied DNA Sciences (APDN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Applied DNA Sciences Inc. (NASDAQ: APDN) (FRA: UDJP) is focused on developing and marketing technology solutions which are DNA-based that can be used in the drug manufacturing and developing markets, as well as for anti-theft, anti-counterfeiting and supply chain security applications.

The firm has its headquarters in Stony Brook, New York and was incorporated in 1983. Prior to its name change in 2002, the firm was known as Datalink Systems Inc. It operates as part of the technology sector, under the technology hardware and semiconductors industry. The firm serves consumers in Asia, Europe and the U.S.

The company is focused on offering DNA-based authentication and security solutions and services which protect intellectual property, supply chains, brands, products and assets of consumers, governments and companies from diversion, fraud, counterfeiting and theft.

The enterprise’s product authentication and security solutions include its molecular tags under the SigNature brand, which offer forensic protection and power for different applications. They can be used to strengthen brand protection efforts. This is in addition to tracking and convicting criminals. It also produces the CertainT supply chain platform which offers proof of product claims for products, items or materials; and its SigNify portable DNA readers and consumable reagent test kits, which offer real-time molecular tags authentication.

The firm recently entered into an agreement with Flora Growth to deploy its CertainT platform as part of the latter company’s product validation and authentication platform for government regulators, distributors and consumers. The move will not only bring in additional revenue into the firm but also encourage more investments into the firm.

Applied DNA Sciences (APDN), closed Tuesday's trading session at $2.8, up 311.1601%, on 117,166,145 volume. The average volume for the last 3 months is 105.295M and the stock's 52-week low/high is $0.6243/$7.88.

Two Hands Corp (TWOH)

Penny Stock General, Shiznit Stocks, QualityStocks, StockRockandRoll, Penny Stock 101, PennyStockLocks, Penny Stock Titans, Profitable Trader Authority, OTCtipReporter, Penny Picks, PennyStockScholar, Damn Good Penny Picks, Small Cap Firm, Fierce Analyst, Stock Commander, PennyStockProphet, StockWireNews, GrowthPennyStocks, Penny Pick Finders, BeatPennyStocks, StockOnion, Buzz Stocks, Epic Stock Picks, Monster Alerts, HotOTC, Wolf of Penny Stocks, Make Penny Stocks Great Again, MicroCapDaily, MassiveStockProfits, Insider Financial, InvestorSoup, Beacon Equity Research, Penny Stock Finder, ProTrader, Stock Preacher, StockHideout, StockStreetWire, Penny Stock Craze, OTCMagic, Penny Stock 106, Penny Stock Prodigy, PennyStockLocks.com, Explicit Penny Picks, Wealth Insider Alert and Winston Small Cap reported earlier on Two Hands Corp (TWOH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Two Hands Corp (OTC: TWOH) is a custom application development firm that is focused on the research and development of software applications.

The firm has its headquarters in Mississauga, Canada and was incorporated in 2009, on April 3rd by Doug Clark. Prior to its name change in September 2016, the firm was known as Innovative Product Opportunities Inc. It serves consumers in Canada.

The enterprise oversees the research, planning, pricing, creative development, tracking and deployment of its diversified solutions to firms in North America. One of its divisions, Gocart.city, is an online grocery delivery marketplace. The division is focused on curating and delivering specialty foods and the freshest produce in Southern Ontario. The enterprise’s other on-demand branches include Cuore Food services and Grocery Originals. Cuore Food operates as its wholesale food distribution branch. Grocery Originals is the firm’s brick-and-mortar grocery store, situated in Mississauga Ontario at the site of the firm’s warehouse. In addition to this, the enterprise offers an encrypted messaging application dubbed Two Hands Gone. Furthermore, it provides fresh-cut, individually packaged vegetables and fruits; Italian themed products like wine, coffee, tea, desserts, pasta and oils; specialized foods, which include gluten-free, artisan and health conscience items; and accessories like aprons, candles, table clothes, tableware and plates.

The company is focused on expanding into new locations, growing its grocery category to more than 2700 items as well as its customer base. In addition to this, it is focused on expanding its delivery area to better meet its customer demand.

Two Hands Corp (TWOH), closed Tuesday's trading session at $0.24, up 139.2822%, on 685,506 volume. The average volume for the last 3 months is 685,506 and the stock's 52-week low/high is $0.05/$5.90.

Cazoo Group (CZOO)

MarketBeat and QualityStocks reported earlier on Cazoo Group (CZOO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cazoo Group Ltd (NYSE: CZOO) (FRA: 8QE0) is an online car retail firm that provides a platform which allows consumers to purchase used vehicles online.

The firm has its headquarters in London, the United Kingdom and was incorporated in 2018 by Alexander Edward Chesterman. Prior to its name change, the firm was known as Capri Listco. The firm mainly serves consumers in the United Kingdom and Europe.

The company is focused on transforming the car purchasing experience across Europe and the UK. Its objective is to make the experience of purchasing a car easy, transparent and convenient. It does so by allowing consumers to seamlessly finance, purchase or subscribe to a vehicle entirely online for either collection or delivery, in 72 hours.

The enterprise offers a range of hatchbacks and sport utility vehicles, which include different hybrid and electric vehicles. Its portfolio of cars includes Fiat, Skoda, Volkswagen, Nissan, Mercedes-Benz, Land Rover, Ford, BMW and Audi. The enterprise also provides car care services, including paint and fabric protection and extended warranty. Its Paint and Fabric protection includes paintwork fading and protection from pollution, among others. Its extended warranty offers cover for electrical and mechanical parts, including clutch and air conditioning, automatic and manual gearbox, diesel particulate filter, engine, cooling system, steering, suspension and braking system.

The company is focused on its continued growth and expansion in Europe and the UK. It plans to capitalize on opportunities that allow them to deliver the best car selling and purchasing experience for consumers, which will be good for its revenues as well as its investments.

Cazoo Group (CZOO), closed Tuesday's trading session at $1.05, up 118.3406%, on 141,306,202 volume. The average volume for the last 3 months is 139.332M and the stock's 52-week low/high is $0.45/$10.13.

Telefonica SA (TEF)

InvestorPlace, MarketBeat, MarketClub Analysis, StreetInsider, Kiplinger Today, The Street, Daily Trade Alert, Zacks, Louis Navellier, SmarTrend Newsletters, TheStockAdvisors, Trades Of The Day, StreetAuthority Daily, Marketbeat.com, The Motley Fool, TradingAuthority Daily, Daily Wealth, The Online Investor, Top Pros' Top Picks, Street Insider, The Street Report, TopStockAnalysts, Daily Markets, Uncommon Wisdom, Barchart, INO.com Market Report, Dividend Opportunities, Investor Guide, InvestorGuide, Trading Markets, Schaeffer's, Market Authority, Stock Tips Network and Lebed.biz reported earlier on Telefonica SA (TEF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Telefonica SA (NYSE: TEF) (OTC: TEFOF) (BME: TEF) (ETR: TNES) (BIT: TEF) is a telecommunications firm that is engaged in the provision of telecommunications services.

The firm has its headquarters in Madrid, Spain and was incorporated in 1924, on April 19th. It operates as part of the telecom services-foreign industry, under the technology sector. The firm serves consumers around the globe, with a focus on those in Europe and Latin America.

The company operates through the Vivo, O2, Movistar and Telefónica brands. Its segments include Telefonica United Kingdom, Telefonica Brazil, Telefonica Spain, Telefonica Germany and Telefonica Hispanoamerica, which was formed by the company’s operators in Argentina, Uruguay, Chile, Ecuador, Peru, Venezuela, Mexico and Colombia.

The enterprise’s mobile and related products and services include mobile data and internet, value added, mobile voice, fixed wireless, roaming, corporate, wholesale, paging and trunking services. Its fixed telecom services include local, domestic, and international long-distance and fixed-to-mobile communications; ISDN accesses; PSTN lines; corporate communications; supplementary value-added services; and telephony information services. It also offers internet and broadband multimedia services, which include internet service provider, retail and wholesale broadband access, network and portal, narrowband switched access and, voice over internet protocol services. This is in addition to leasing and selling handset equipment and offering TV/video services. The enterprise serves both corporate and residential customers.

The company, which is party to a joint business venture with Virgin Media O2 and Liberty Global, remains focused on acquiring businesses which would help it consolidate and expand its presence in the telecommunications industry. This will help create shareholder value and bolster its growth significantly.

Telefonica SA (TEF), closed Tuesday's trading session at $4.4, up 0.456621%, on 1,349,849 volume. The average volume for the last 3 months is 1.235M and the stock's 52-week low/high is $3.971875/$5.221563.

Pitney Bowes (PBI)

InvestorPlace, Kiplinger Today, MarketClub Analysis, Dividend Opportunities, The Street, StocksEarning, StreetAuthority Daily, StreetInsider, Schaeffer's, Daily Trade Alert, TradersPro, MarketBeat, TopStockAnalysts, Daily Markets, Investor Update, Trading Concepts, Barchart, Zacks, Market Intelligence Center Alert, StockMarketWatch, BUYINS.NET, Wealth Insider Alert, SmarTrend Newsletters, Wall Street Daily, The Online Investor, Trades Of The Day, Top Pros' Top Picks, The Growth Stock Wire, TheStockAdvisors, StockEarnings, CRWEFinance, Investing Daily, Dynamic Wealth Report, INO.com Market Report, Forbes, FNNO Newsletters, Eagle Financial Publications, ChartAdvisor, Investiv, CrashTrade, Investopedia, Market FN, Marketbeat.com, Profit Confidential, ProfitableTrading, Schaeffer’s, Stock Research Newsletter, Street Insider, The Motley Fool, The Street Report, Tradespoon, Trading Markets, TradingMarkets, Wyatt Investment Research and QualityStocks reported earlier on Pitney Bowes (PBI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pitney Bowes Inc. (NYSE: PBI) (FRA: PBW) (BCBA: PBI) is a shipping and mailing firm that is focused on providing logistics, technology and financial services to government, retailers, large enterprises, and small and medium-sized business clients.

The firm has its headquarters in Stamford, Connecticut and was incorporated in 1920, on April 23rd by Walter Bowes and Arthur H. Pitney. Prior to its name change, the firm was known as Pitney Bowes Postage Meter Company. It operates as part of the integrated freight and logistics industry, under the industrials sector. The firm serves consumers in Canada, the United States and internationally.

The company operates through the SendTech solutions, Presort services and Global e-commerce segments. The SendTech segment is involved in providing digital and physical mailing and shipping technology solutions, services, financing, supplies and other applications for sending, receiving and tracking of flats, parcels and letters. The Presort segment is engaged in the provision of mail sorting services, which enable clients to qualify volumes of marketing mail, first-class mail, bound and packet mail for postal work sharing discounts. On the other hand, the e-commerce segment is focused on providing cross-border solutions, domestic parcel services and digital delivery services. The company markets its products, services and solutions through its direct and inside sales force, digital channels, direct mailings and regional and global partner channels.

The enterprise recently announced its latest financial results, with its CEO noting that they had observed an improvement in its domestic parcel network service levels which were driving growth in revenues from domestic parcels and bringing in new clients.

Pitney Bowes (PBI), closed Tuesday's trading session at $3.29, off by 1.2012%, on 2,377,263 volume. The average volume for the last 3 months is 2.024M and the stock's 52-week low/high is $3.17/$8.41.

Porch Group (PRCH)

MarketBeat, Trades Of The Day, MarketClub Analysis and InvestorPlace reported earlier on Porch Group (PRCH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Porch Group Inc. (NASDAQ: PRCH) (FRA: 32RD) is a software firm that is engaged in the development and operation of a vertical software platform and services to home service industries.

The firm has its headquarters in Seattle, Washington and was incorporated in 2011 by Matt Ehrlichman. It operates as part of the software-application industry, under the technology sector. The firm serves consumers around the globe, with a focus of those in Canada and the United States.

The company operates through the Insurance and Vertical software segments. The vertical software segment is involved in providing software and services to home service firms. It also affords early access to home owners and home buyers. This segment has 3 types of customers; service providers like warranty, insurance security and moving firms as well as Internet/TV providers, consumers like home owners and home buyers; and home service firms like home inspectors. This segment operates through the V12, Rynoh, Porch.com, Palm-Tech, iRoofing, ISN, HireAHelper and Floify brands. On the other hand, the insurance segment is engaged in the provision of property-related insurance policies through its own risk-bearing home warranty company and its risk-bearing carrier and independent agency. This segment operates through the Homeowners of America, Elite Insurance Group and American Home Project brands.

The company recently expanded its homeowners’ insurance services to Delaware, which will help grow its national footprint as it works to make moving and homeownership easy. This move also opens the company up to new growth opportunities, which will help create shareholder value.

Porch Group (PRCH), closed Tuesday's trading session at $1.81, off by 4.2328%, on 2,212,286 volume. The average volume for the last 3 months is 2.212M and the stock's 52-week low/high is $1.80/$27.50.

China Green Agriculture (CGA)

The Street, SmarTrend Newsletters, TradersPro, StreetInsider, InvestorPlace, Zacks, TheStockAdvisors, Greenbackers, MarketBeat, All about trends, StockMarketWatch, Microcapmillionaires, FeedBlitz, Daily Profit, Marketbeat.com, SmallCapVoice, InvestorsUnderground, MarketClub Analysis, StockEgg, Wall Street Resources, The Online Investor, Super Stock Picker, China Stock Alerts, Hit and Run Candle Sticks, OTC Journal, SmallCapNetwork, Equities.com, DrStockPick, CRWEFinance, BUYINS.NET, BullRally, CRWEWallStreet, CRWEPicks, BestOtc, CoolPennyStocks, PennyOmega, Wyatt Investment Research, Streetwise Reports, StockRich, StockHotTips, SpeculatingStocks, Momentum Trades, PennyStockVille, HotOTC, PennyInvest, Penny Sleuth, Penny Invest, National Inflation Association, MadPennyStocks, Investor Ideas and PennyToBuck reported earlier on China Green Agriculture (CGA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

China Green Agriculture, Inc. (NYSE: CGA) (FRA: GR0A) is focused on conducting research on, developing, producing and selling a range of fertilizers and agricultural products.

The firm has its headquarters in Xi'an, China and was incorporated in 1987, on February 6th by Tao Li. It operates as part of the agricultural inputs industry, under the basic materials sector. The firm serves consumers in the People’s Republic of China.

The company operates through the Sales variable interest entities, Yuxing, Gufeng and Jinong segments. The variable interest entities segment comprises of subsidiary company sales while the Jinong segment includes fertilizer products, with focus on compound fertilizer based on humic acid. On the other hand, the Yuxing segment is involved in developing and producing agricultural products like colored seedlings, flowers, vegetables and top-grade fruits. The Gufeng segment is made up of mixed organic-inorganic compound fertilizer, highly-concentrated water-soluble fertilizers, slow-release fertilizers, organic compound fertilizer, blended fertilizer and compound fertilizer.

The enterprise sells its decorative flowers to end-users like government agencies, luxury hotels and flower shops; seedlings to city planning departments; and vegetables and fruits to upscale restaurants and supermarkets. It markets its fertilizer products to private retailers and wholesalers of agricultural farm products. This is in addition to exporting its products via contracted distributors to countries like India as well as some in Africa.

The firm remains focused on bringing in additional revenues by expanding its distributor network in the country and creating additional value for its shareholders. This will positively influence investments into the firm and bolster its overall growth.

China Green Agriculture (CGA), closed Tuesday's trading session at $4.56, up 3.6364%, on 2,025 volume. The average volume for the last 3 months is 2,025 and the stock's 52-week low/high is $4.3768/$12.4789.

Turkcell Iletisim Hizmetleri (TKC)

The Online Investor, InvestorPlace, MarketBeat, The Street, MarketClub Analysis, Kiplinger Today, Daily Trade Alert, Marketbeat.com, SmarTrend Newsletters, Zacks, Bull Warrior Stocks, Trades Of The Day, StocksEarning, StreetInsider, FNNO Newsletters and BUYINS.NET reported earlier on Turkcell Iletisim Hizmetleri (TKC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Turkcell Iletisim Hizmetleri AS (NYSE: TKC) (IST: TCELL) (BMV: TKCN) is a converged communication and technology services firm that is engaged in the provision of digital services.

The firm has its headquarters in Istanbul, Turkey and was incorporated in 1993, on October 5th by Hüseyin Murat Vargi and Mehmet Ermin Karamehmet. It operates as part of the telecom services industry, under the communication services sector. The firm serves consumers in Turkey, the Netherlands, Germany, Northern Cyprus, Belarus and Ukraine.

The company operates through the Techfin, Turkcell International, All other and Turkcell Turkey segments. The Techfin segment includes the operations of Turkcell Sigorta, Paycell, Turkcell Odeme and Turkcell Finansman while the International segment includes telecommunications operations in various emerging market geographies. On the other hand, the Turkey segment includes operations of entertainment and information services in Azerbaijan and Turkey while the All Other segment comprises of operations of non-group call centers.

The enterprise offers digital business services, which include IoT, e-transformation, cyber security, managed services, big data, data center and cloud solutions. It also offers a range of software, hardware, devices and financing solutions. The enterprise also provides work contact services comprising of customer loyalty and programs, fixed business internet and business phone and mobile communications. This is in addition to providing TV and home internet services. Furthermore, it offers TV+, which allows subscribers to watch series and other TV content wherever they want and whenever.

The firm remains focused on managing its operations effectively and improving its growth, which will positively influence investments and revenues into the firm.

Turkcell Iletisim Hizmetleri (TKC), closed Tuesday's trading session at $2.38, off by 0.833333%, on 438,066 volume. The average volume for the last 3 months is 437,206 and the stock's 52-week low/high is $2.33/$5.00.

Royal Gold Inc. (RGLD)

TopStockAnalysts, Streetwise Reports, StreetAuthority Daily, InvestorPlace, TradingAuthority Daily, The Street, Daily Wealth, MarketBeat, Top Pros' Top Picks, StreetInsider, Daily Trade Alert, SmarTrend Newsletters, TheStockAdvisor, All about trends, Energy and Capital, Zacks, Money Morning, MarketClub Analysis, The Growth Stock Wire, TheStockAdvisors, Trades Of The Day, Dividend Opportunities, QualityStocks, Marketbeat.com, Wyatt Investment Research, Barchart, Wealth Daily, Lebed.biz, Uncommon Wisdom, Investor Update, Schaeffer's, Daily Profit, Investment U, Money and Markets, National Inflation Association, Stockhouse, The Online Investor, Traders For Cash Flow, TradingMarkets, Greenbackers, Forbes, Outsider Club, Kiplinger Today, Trade of the Week, Weekly Wizards, Market Intelligence Center Alert, Inside Investing Daily, Bourbon and Bayonets, BestChartNow, Wealth Insider Alert, AllPennyStocks, FNNO Newsletters, ChartAdvisor, GorillaTrades, Dynamic Wealth Report, One Hot Stock, INO.com Market Report, Investing Futures, The Best Newsletters, Investopedia, StocksEarning, Stocks That Move, Market Authority, Market FN, Stansberry Research, Short Term Wealth, Profits Run, PowerRatings Stocks, Penny Stock Chaser and Hit and Run Candle Sticks reported earlier on Royal Gold Inc. (RGLD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

As the world adopts the use of electric vehicles, the increasing demand for nickel, lithium, cobalt and other key ingredients needed for batteries outpaces the supply, which has been affected by a general lack of investment and pandemic-related logistical woes. This, coupled with increasing concerns over the dominance that China exhibits in the market and the slowing global economy, has led to an increase in prices and, in turn, accelerated the race to secure supply.

For instance, General Motors announced last week that it had entered into a number of supply deals for the raw materials it requires for its electric vehicle fleet. This comes less than a week after Ford disclosed a list of suppliers of inputs, which include enough nickel from Indonesia and lithium from Argentina to manufacture more than half a million electric vehicles annually.

House Mountain Partners President Chris Berry stated that these deals highlighted the importance of entering into agreements with multiple, long-term raw material sources. House Mountain Partners is an industry consultancy.

Auto manufacturers have for a while now dealt with delayed deliveries across the electric vehicle space, which has aggravated supply-surety concerns. This has prompted them to demonstrate supply chain management by entering into agreements with producers of raw materials, which may play a key role in their progression.

General Motors is now party to supply deals with three different companies: Posco Chemical Co., Livent Corp and LG Chem Ltd. Its Posco Chemical deal will involve the supply of cathode materials to GM from next year until 2025 while its Livent Corp deal is a multiyear agreement to secure lithium. On the other hand, its deal with LG Chem involves the supply of almost 970,000 metric tons of cathode material to the company until 2030.

Ford Motor Company revealed that through its suppliers, it had secured enough battery minerals to manufacture about 600,000 electric vehicles a year by late 2023. This will be quite an increase from the 27,100 battery-powered vehicles the company sold in America in 2021.

The company stated that it had entered into contracts with suppliers representing 60GWh of yearly battery capacity, noting that these suppliers had regional facilities to provide materials. This highlights the strides it has made to count less on refining and manufacturing done in China. This is because depending on China now, unlike in the past, is seen as a vulnerability amid political and trade tensions that are encouraging many to rethink international supply lines.

As the race for battery metals heats up, it is likely to have a positive effect on other metals, and companies such as Royal Gold Inc. (NASDAQ: RGLD) could be in for a bullish run over the coming years.

Royal Gold Inc. (RGLD), closed Tuesday's trading session at $104.33, off by 1.1933%, on 703,630 volume. The average volume for the last 3 months is 703,630 and the stock's 52-week low/high is $92.01/$147.70.

The QualityStocks Company Corner

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

  • The popularity of online gaming is set to be further boosted through the advent of ‘Metaverse’ gaming
  • Metaverse gaming allows for users to enhance their virtual gaming experience, interacting socially with their peers to mimic a realistic, casino experience in the comfort of their homes
  • BUThe development is also of great appeal to gaming providers, given the higher levels of transparency, security, and privacy involved relative to traditional casinosLLET3
  • The growth in online gaming has spurred the creation of thousands of online gaming providers, with the vast majority opting to procure their operational systems from third-party ‘SaaS’ providers
  • The trend has benefitted GMGI, with the company reporting its 15th consecutive quarter of profitability in 2Q2022

Early this year, a JP Morgan report boldly stated that the metaverse “would likely infiltrate every sector in some way in the coming years with the market opportunity estimated at over $1 trillion in yearly revenues”. Online gaming enjoyed a dramatic leap in popularity over the past year, as a result of the Covid-19 pandemic; in fact, and in the first quarter of FY2022, online gaming providers on average saw their revenues rise by 24 percent year-over-year. However, the advent of the metaverse may now usher in the new era of growth for the online gambling sector, one which Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems, and gaming content, is well placed to exploit.

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.

Technology

Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Tuesday's trading session at $4, up 0.125156%, on 16,878 volume. The average volume for the last 3 months is 16,878 and the stock's 52-week low/high is $3.29/$10.72.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) patented DehydraTECH(TM) has been regarded as one of the most innovative drug delivery technologies in years, proving useful in delivering a wide range of active pharmaceutical ingredients in a more palatable and effective way. Studies have also demonstrated DehydraTECH’s ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances, with cannabinoids by as much as 27x compared to standard industry formulations, a benefit that opens significant possibilities for important drug delivery. “DehydraTECH’s application in the cannabis sector is seeing a boom, particularly with the recent expansion of Boldt Runners Corporation, a DehydraTECH licensee, into Europe, Japan and South Africa… As Lexaria’s list of licensees continues to grow, more consumers will benefit from the DehydraTECH technology. The company is confident that, as the adoption of this technology grows, it will not only help its partners offer clients superior performance and experiences, but also ramp up shareholder value,” reads a recent article. Chris Bunka, Lexaria’s CEO, was quoted as saying, “Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients. We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.” To view the full article, visit https://cnw.fm/dftgo

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Tuesday's trading session at $2.78, up 0.724638%, on 34,067 volume. The average volume for the last 3 months is 33,967 and the stock's 52-week low/high is $1.85/$7.20.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, will be the topic of discussion in an upcoming Benzinga YouTube channel interview. The live interview, hosted by Zunaid Sulemanet and slated for Aug. 4, 2022, at 1:30 p.m. ET will feature Mullen CEO and chair David Michery. According to the announcement, Michery’s previous interviews with Benzinga have been some of its most popular events, with viewers from around the world watching the live one-on-one discussions. “I look forward to connecting with Benzinga later this week, especially after a recent health event that kept me away from the office for a short while,” said Mullen CEO and chair David Michery in the press release.  “I have some exciting developments to share and look forward to connecting with Benzinga listeners.” To view the full interview, visit https://ibn.fm/0D2RI. To view the full press release, visit https://ibn.fm/DziDc

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $0.9154, up 5.5946%, on 53,707,341 volume. The average volume for the last 3 months is 52.762M and the stock's 52-week low/high is $0.52/$15.90.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora (NASDAQ: FLGC) is a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands. The company today announced a joint venture agreement with Pharma Indigena Misak Manasr Sas (“Manasr”), the largest indigenous tribe in Colombia, on the development of cultivation best practices, manufacturing, export, and marketing of cannabis and cannabis containing products. “We are honored to be given opportunity to work hand-in-hand with the Misak people,” said Luis Merchan, Flora’s chairman and CEO. “Through this partnership, we will collaborate with the tribe on the processing and distribution of their Colombian-grown cannabis while offering Manasr a powerful platform for product distribution. In return, Flora will be able to leverage the tribe’s unique regulatory positioning to expedite exports and increase global market penetration of Colombian cannabis goods. We look forward to a long-standing relationship with such a powerful community partner.” To view the full press release, visit https://ibn.fm/nPjzZ

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Tuesday's trading session at $0.68, up 8.0566%, on 414,233 volume. The average volume for the last 3 months is 405,692 and the stock's 52-week low/high is $0.586/$21.45.

Recent News

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF)

The QualityStocks Daily Newsletter would like to spotlight Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF).

Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) (FRA: 6BC0), a publicly-traded investment company, today announced its second quarter 2022 financial results, including record revenue, gross profit and net earnings of its wholly-owned portfolio company Belle Pulses Ltd. “Belle Pulses’ performance is exceeding expectations, and we remain very pleased with the growth rate and strong ability to execute from Tony and Francis Gaudet as they continue to lead Belle Pulses. The team delivered record revenue and record gross profit as they fulfill their mission to feed families globally, while our CPG investments continue to scale rapidly across channels. I am confident we are on the right path, and the market will appreciate how robust EWG’s portfolio companies are becoming,” said Eat Well Group’s president and CEO Marc Aneed. “Food security has become a major concern around the world. From severe weather to disrupted supply chains, and global conflicts, making our investment thesis more timely than ever. Real food, right now, is what the world needs, and that’s what Eat Well’s portfolio companies are supplying every week. We are incredibly excited for where we are headed and expect the management teams to continue ramping up well into the future.” To view the full press release, visit https://ibn.fm/n3kTb

Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF), headquartered in Vancouver, British Columbia, is a publicly traded vertically integrated plant-based foods company combining the best of agribusiness, foodtech, and CPG brands to supply the world with innovative, delicious, and better-for-you foods. The company supplies Beyond Meat, Ingredion, Nestle, General Mills and more. It is on track to generate $60 million in revenue for 2021 and is projecting $100 million in revenue for 2022.

Eat Well’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health and wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. Eat Well’s strategic advisory board includes pioneers in the plant-based foods industry, including HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, and Jeff Dunn, CEO of Bolthouse Farms who previously held senior leadership positions at both Campbell Soup Company and The Coca Cola Company.

The company’s plant-based investment thesis is centered on growing its seed-to-market operations, which include raw ingredients, processing, pulse fractionation, unique IP and premium consumer packaged goods (CPG). Eat Well Group is building a unique ecosystem that can supply these essential cornerstone needs for society. The company has plant-based foods and nutrition experts specializing in the latest science and original thinking for what consumers want most – high quality and affordability in healthy, clean and simple products.

Eat Well focuses on intellectual property, product portfolio development and long-term value creation for stakeholders in a rapidly expanding industry. As an emergent sector globally, plant-based foods represent a double-digit annual growth category, with more than 35% of the world’s supply of pulse proteins coming from Canada.

Portfolio

On July 31, 2021, Eat Well Group acquired Belle Pulses Ltd., one of the top pulse processors in Canada. Belle Pulses has been operating for over 40 years and had over $60 million in sales in 2020. The company counts a broad range of customers in over 35 countries, including global strategic food companies and major ingredient distributors. Currently, Belle produces nearly 100,000 tons of fully traceable seed and product, yielding over 26,000 tons of pure plant protein.

Eat Well also owns 100% of Sapientia Technology Inc. Led by Dr. Eugenio Bortone – one of the world’s preeminent food scientists and extrusion processing experts and the inventor of Frito-Lay’s Twisted Cheetos – Sapientia has filed four patents around the “protein curl” and crispy-puff-style snack. By focusing on texture and crunch, Sapientia’s patents solve one of the major problems that large scale snack food companies have struggled with for years – how to offer appealing texture and flavor in a guilt-free, not fried, natural and healthy alternative to the majority of snack food products available today.

Eat Well owns a 51% share of Amara Organic Foods, with an option to acquire additional ownership up to 80 percent. Amara, one of the fastest-growing baby food brands in America, is a food technology company that uses science and proprietary IP that locks in taste and texture to make healthy, organic, non-GMO, plant-based, convenient baby and children’s food possible for modern-day families. From baby food to toddler food and beyond, Amara is driven by the belief that setting kids on the right path from a young age will help them live better, feel better and think better for the rest of their lives. Amara’s revenues have grown by more than 400% since January 2021, and the brand’s success has drawn media coverage from business news outlets including Forbes and TechCrunch.

Market Outlook

According to an August 2021 report from Bloomberg Intelligence, the plant-based foods market is expected to experience explosive growth, comprising up to 7.7% of the global protein market by 2030 at a value of over $162 billion, up from $29.4 billion in 2020. Bloomberg notes that plant-based alternatives are here to stay, and that consumption will grow rapidly. Plant-based food sales in 2020 grew twice as fast as overall food sales, according to Polaris Market Research.

Pulse proteins (fava, yellow pea, etc.) are a foundational ingredient to most plant-based foods due to their high protein content and their readily available, affordable supply.

Many analysts view the food tech market as similar to the early days of the Internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize the way society functions and people experience nutrition.

The sector continues to experience significant M&A transactions. Recently, Sol Cuisine was acquired by PlantPlus Foods LLC, a major South American protein producer, in an all-cash transaction valued at approximately $126 million, or 6x revenue.

Management Team

Marc Aneed is President and Director of Eat Well Group. His 20-year career in CPG started at The Quaker Oats Company/PepsiCo, where he worked on iconic brands like Gatorade. He previously was at Glanbia PLC, a global nutrition company, where he led Amazing Grass, a leading plant nutrition and supplement company with over $100 million in retail sales. He also led Glanbia’s Sports Nutrition brands in North America with over $750 million in retail sales. Mr. Aneed has launched dozens of successful consumer products, driving over $1 billion in collective retail sales.

Mark Coles is the company’s Chief Investment Officer. He is a veteran CPG senior executive specializing in the plant-based foods sector. For the past decade, Mr. Coles has spearheaded global plant-based start-up initiatives, culminating in a 2020 acquisition by an international New York Stock Exchange-listed food ingredient company. He has over 25 years of experience in CPG-focused strategy, mergers and acquisitions and project financing.

Patrick Dunn is Eat Well Group’s Vice President, Finance. He is the founding partner of Dunn, Pariser & Peyrot and has a track record of building highly successful agribusinesses throughout North America and other international markets. As a testimony to his business portfolio work, Mr. Dunn and his firm have won multiple industry awards for accounting, finance and business management.

Barry Didato is the company’s Vice President, Strategy. He is focused on the development of strategic revenue channels, sales partnerships, and international distribution for Eat Well Group. Mr. Didato brings extensive strategic sales capabilities and an extensive network of contacts in the industry to the company. Prior to joining Eat Well Group, he served for over 18 years as a senior advisor for several ultra-high net worth family offices and numerous innovative wellness, nutrition, medical, and food businesses.

Strategic Advisory Board

HRH Prince Khaled bin Alwaleed bin Talal Al Saud, Founder and Chief Executive Officer of KBW Ventures, is a firm supporter of clean energy and the humane treatment of animals. He is also a vocal supporter of the private sector in the Middle East. A member of the Saudi Arabian Royal Family, Prince Khaled was born in Stanford and spent his youth in Riyadh under the mentorship of his father, philanthropist HRH Prince Alwaleed bin Talal Al Saud, Chairman of Kingdom Holding Company. He is also the Founding Chairman of KBW Investments and serves across several boards. He invests in an array of successful but diverse global businesses – from promising technology startups to established companies. Today, with holdings on three continents, Prince Khaled stands at the gateway between the Middle East’s evolving economies and the Western world. Consistently, Prince Khaled’s focus is on ventures and ideas at the intersection of innovation and economic growth.

Jeff Dunn has over 30 years of experience in agriculture and packaged food, including senior leadership positions with Bolthouse Farms, Campbell Soup Company and The Coca Cola Company, among others. He is an Operating Partner at Butterfly and focuses primarily on the agriculture & aquaculture and food & beverage product sectors. Prior to joining Butterfly, Mr. Dunn was the President of the Campbell Fresh division of Campbell Soup Company from 2015 to 2016, where he was in charge of building Campbell’s scale and accelerating its growth in the rapidly expanding packaged fresh segments and categories across the retail perimeter.

Eat Well Investment Group Inc. (OTC: EWGFF), closed Tuesday's trading session at $0.1853, up 7.5824%, on 6,500 volume. The average volume for the last 3 months is 6,500 and the stock's 52-week low/high is $0.13158/$1.00.

Recent News

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF)

The QualityStocks Daily Newsletter would like to spotlight EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF).

  • EverGen boasts long term contracted offtakes with key energy providers such as FortisBC
  • Offtakes mean that company has buyers lined up before production begins; these agreements are key in securing relatively stable and predictable cash flows
  • 20-year offtake agreement with utilities like FortisBC enhances certainty for EverGen’s business and allows it to build new production capacities to convert more organic waste into RNG

Although a young company, EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF) appears poised to establish itself as one of the leaders in the renewable natural gas space (“RNG”) – especially in its home Canada. As a developer, owner and operator of projects that take organic waste and convert it into renewable natural gas, EverGen is operating in the burgeoning market as a number of Canadian utilities seek green energy alternatives. Hitting ambitious climate targets means that these companies increasingly seek to secure a steady stream of green energy supplies. Here, renewable gas offers an effective solution that doesn't cause significant disruption to consumers, either financially or operationally. As a result, the demand for RNG is expected to remain strong. EverGen's business model is designed to leverage market opportunities like these through offtakes, or long-term partnerships with energy providers that increasingly seek new ways to achieve ambitious green targets.

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) is developing Canada’s Renewable Natural Gas Infrastructure Platform, starting on the west coast in British Columbia. The company is combating climate change and helping communities contribute to a sustainable future by acquiring, developing, building, owning and operating a portfolio of renewable natural gas (RNG), waste-to-energy, and related infrastructure projects.

While EverGen is currently focused on British Columbia, its continued growth is expected across other regions of North America. RNG is produced differently than conventional natural gas, without drilling wells. RNG is derived from biogas, which is captured from decomposing organic waste in landfills, food waste, agricultural waste matter and wastewater from treatment facilities. This waste feedstock is supplied to an anaerobic digester which contains bacteria that breaks down organic matter in the absence of oxygen. The resulting biogas is captured and cleaned to create carbon neutral or carbon negative RNG to be used by the existing North American gas pipeline grid. By capturing these emissions and transforming them into RNG, then combusting into CO2, the overall greenhouse gases (GHG) impact is materially less potent than allowing natural decomposition to release methane into the atmosphere. Liquid and solid digestate matter is a byproduct of the RNG production process and is used as fertilizer and in other applications.

EverGen operates three projects in British Columbia. The company was incorporated in 2020 and went public in 2021, with its common shares listed on the TSX Venture Exchange under ticker symbol ‘EVGN’. In February 2022, EverGen’s common shares began trading on the OTCQB Venture Market in the U.S. under ticker symbol ‘EVGIF’. The company is headquartered in Vancouver.

Portfolio Projects

Fraser Valley Biogas is one of three projects in EverGen’s portfolio. Located in Abbotsford, British Columbia, the facility has been digesting manure and off-farm organics since 2011 and was the first agricultural digester in Canada to produce RNG. The RNG generated through this project is part of a FortisBC program to supply renewable gas to homes, businesses and other customers. Fraser Valley Biogas also provides Abbotsford farms with renewable fertilizer via the digestate produced. EverGen acquired Fraser Valley Biogas early in 2021 and is currently enhancing and expanding the facility. These optimization projects resulted in record production during the month of September 2021, supporting the growing demand for RNG in British Columbia. Optimization activities contributed an additional 18% of RNG production for September and a 9% higher year-to-date production compared to the previous year. The facility produces approximately 80,000 gigajoules of RNG, enough to heat more than 1,000 homes for a year.

Net Zero Waste Abbotsford, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and RNG expansion project. The British Columbia Utilities Commission recently approved a 20-year offtake agreement between the facility and FortisBC, an electricity and gas utility. Under this agreement, FortisBC will purchase up to 173,000 gigajoules of RNG annually for injection into its natural gas system upon completion of an anaerobic digester project at Net Zero Waste Abbotsford. Once construction is complete, this project is expected to produce enough energy to meet the needs of more than 1,900 homes.

Sea to Sky Soils, a wholly owned EverGen subsidiary and portfolio project, is an existing composting and organic processing facility and potential future RNG expansion project which has been operating near Pemberton, British Columbia, on Lil’wat Nation land since 2012. The Lil’wat Nation is a key partner and supporter of the facility, which has employed a majority of its staff from the First Nation since inception. The Sea to Sky Soils facility processed approximately 160 percent of its forecast tonnage in the second half of 2021. In total, Sea to Sky Soils processed approximately 36,000 tons of organic waste in 2021. The facility is working with the Ministry of Environment to expand its operational capacity in 2022. EverGen has partnered with local municipalities – including Metro Vancouver and the municipality of Pemberton – for the delivery of additional organic waste to the facility. The facility is an important part of EverGen’s RNG infrastructure platform and serves as a source of valuable feedstock to support the company’s existing and future operations.

Market Outlook

A report from Global Market Insights states that the biogas market is projected to see significant growth over the next few years, driven by a shifting preference to utilize biogas to reduce emission levels from traditional fuels. Escalating RNG usage by gas utilities as a sustainable and low carbon alternative to supply heat and electricity in industries and buildings will further stimulate growth. RNG is increasingly deployed across the transport sector, especially for heavy vehicles and vessels, to abate GHG emissions.

Many North American gas utilities have set RNG targets of 5% to 15% of production by volume in 2030, compared to less than 1% by volume in 2020. FortisBC has a goal of including 15% RNG in its gas supply by 2030. EverGen believes this presents a potential C$16 billion+ opportunity for RNG producers.

Management Team

Chase Edgelow is co-founder and CEO at EverGen. He has over 15 years of specialized private investment, finance, and technical expertise in the energy and infrastructure sectors. His background is as a Facilities Engineer with Petro-Canada, independently managing energy infrastructure capital projects located in western Canada. He holds a Professional Engineer designation from the province of Alberta.

Mischa Zajtmann is co-founder and President at Evergen. He has 15 years of experience providing consulting and management for Canadian and American companies in the natural resources and energy space. He is a corporate securities lawyer who began his career at Blake, Cassels & Graydon LLP. His J.D. is from the University of Saskatchewan Law School. He’s a member of the British Columbia Bar.

Sean Mezei is COO at EverGen. He has 20 years of experience in the RNG industry, having served previously as the president of Greenlane Biogas and as a senior manager at QuestAir, and founder and president of Dekany Consulting. He was a co-chairman of the American Biogas Council’s RNG working group for six years. He has been a Registered Professional Engineer in the province of British Columbia since 1994.

Natasha Monk is CFO at EverGen. She is a CPA with 12 years accounting, financial reporting, and tax experience in public practice and industry. She is currently a partner at Affirm LLP, where she advises and consults to a wide variety of companies in multiple industries across public and private sectors. Prior to joining EverGen, she worked at KPMG. She graduated from the University of Calgary.

EverGen Infrastructure Corp. (OTCQB: EVGIF), closed Tuesday's trading session at $2.15, even for the day. The average volume for the last 3 months is 10 and the stock's 52-week low/high is $2.12/$4.21.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

Over the past decade or so, plenty of studies have found marijuana to be effective at treating the symptoms of a variety of medical conditions. However, most of this research is in its infancy, and experts unanimously agree that we need a lot more clinical trials to definitively prove marijuana’s medical potential. In Colorado, MedPharma Research, a leading research company in the medical cannabis field, recently announced that it had been granted funding to research the efficacy of marijuana in Alzheimer’s patients. The company submitted a proposal to the Colorado State University Institute of Cannabis Research’s (ICR) FY23 Cannabis Research Opportunity and was ultimately selected for funding. This and other ongoing marijuana studies are likely to be followed closely by the cannabis industry and its established actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) since they will add onto the scientific documentation debunking the thinking at the DEA that marijuana has no medical value and should therefore remain a highly controlled substance.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Tuesday's trading session at $0.0117, even for the day, on 762,560 volume. The average volume for the last 3 months is 567,560 and the stock's 52-week low/high is $0.0102/$0.072.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

New research on student well-being in the pandemic period has identified sleep difficulties and worsened financial situation as indicators of people with a heightened risk of developing mental health conditions. The findings, which were reported in the “BJPsychOpen” journal, will be useful to institutions of higher learning because they can help identify students with a high risk of developing mental health conditions and offer enhanced support to those students. For their study, researchers at the University of Warwick carried out a survey of more than 500 young adults who weren’t in higher education and almost 900 university students, between July and September 2020. They conducted a follow up of about 200 of the university students after six months. Financial and other stressors are increasing amid the ongoing uncertainty and economic upheavals around the world, which means companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) that are researching new treatments for mental disorders need to add more vigor to their efforts so that these illnesses are treated effectively without exposing patients to unwanted side effects.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Tuesday's trading session at $0.6101, off by 1.5968%, on 1,059,414 volume. The average volume for the last 3 months is 1.05M and the stock's 52-week low/high is $0.3903/$3.38.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

  • CNS Pharmaceuticals is undertaking a Berubicin clinical development program targeting glioblastoma multiforme (“GBM”), the most common and devastating primary malignant brain tumor
  • GBM has an incidence rate of 3.21 per 100,000 in the U.S. and up to 5 per 100,000 globally, with studies noting that the latter figure is rising
  • CNS recently received approval for a protocol amendment as part of its potentially pivotal study evaluating the efficacy and safety of Berubicin for the treatment of GBM
  • The amendment expands eligibility for its potentially pivotal study to patients who have received additional treatments as part of the first-line therapy
  • CNS is looking to expand the scope and outreach to patients for the multicenter trial by opening clinical sites globally

Biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) recently marked an important milestone in its pursuit of novel treatments for primary and metastatic cancers in the brain and central nervous system, one of which is glioblastoma multiforme (“GBM”), an area of significant unmet medical need. CNS is currently recruiting patients for a potentially pivotal Phase II study evaluating the efficacy and safety of Berubicin, its lead drug candidate for treating GBM. The open-label, multicenter, randomized, parallel study, which commenced in Spring 2021 with an estimated primary completion date of Fall 2024, is expected to have an enrollment of more than 200 adult patients.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $0.2132, off by 3.0909%, on 243,351 volume. The average volume for the last 3 months is 242,826 and the stock's 52-week low/high is $0.20/$1.73.

Recent News

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

  • Biotech innovation company, Aditxt, Inc (“Aditxt” or the “Company”) is developing and commercializing technologies focused on monitoring and reprogramming the immune system 
  • BULLTheir ground-breaking ADi(TM) immune reprogramming platform will be initially directed towards the treatment of psoriasis, type 1 diabetes and skin allograftingET2
  • The Company has also recently begun to commercialize their AditxtScore(TM) proprietary immune mapping technology, which is designed to provide individuals with personalized reports on their immune system
  • The AditxtScore(TM) system is initially focused on providing customers with reports looking into their vulnerability and immune response to SARS-CoV-2 and its known variants

Every 9 minutes, a person is placed on an organ transplant waiting list in the United States. Yet, due to a critical shortage of organs, only 41,000 transplantations took place in 2021 (https://ibn.fm/gmVnu). In spite of a wide array of medical innovations in recent years, industry data suggest that approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years, highlighting the critical need for a practical and cost-effective solution to harmful immune responses. Aditxt (NASDAQ: ADTX) has sought to address this medical conundrum through the creation of immune reprogramming technologies which are being developed to retrain the immune system to induce tolerance to transplanted organs, self-tissues (autoimmune diseases), and allergens. Aditxt (NASDAQ: ADTX) was featured in the Bell2Bell Podcast, a part of IBN’s (InvestorBrandNetwork) sustained effort to provide specialized content distribution via widespread syndication channels. Amro Albanna, co-founder, chairman and CEO of Aditxt, joined the latest episode to provide an overview of the company and discuss its business model. “We are a biotech innovation company, and our focus is on immune diseases. The reality is that immune diseases are caused either by someone having too little immune response or too much immune response,” Albanna said. “When you have too little immune response and you’re dealing with COVID-19, we all understand the story, and that applies to other viral diseases. Too much immunity is also not a good thing. When you have too much immune response, you get into the area of autoimmune diseases – multiple sclerosis, type I diabetes and psoriasis. These all happen when our immune system begins to overreact and attack our own tissues and cells.” To view the full press release, visit https://ibn.fm/p38Y6

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.

AditxtScore™

AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.

ADi™

ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

  • Can be made into a product
  • Does not require additional hospitalization
  • Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

  • 8 U.S. patents
  • 4 pending U.S. patent applications
  • 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

  • Autoimmune diseases and Type 1 Diabetes
  • Organ transplantation and a method of producing plasmid DNA to prevent immune activation
  • Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.


Aditxt Inc. (NASDAQ: ADTX), closed Tuesday's trading session at $0.1527, off by 0.130804%, on 1,415,968 volume. The average volume for the last 3 months is 1.367M and the stock's 52-week low/high is $0.1242/$3.95.

Recent News

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF)

The QualityStocks Daily Newsletter would like to spotlight Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF).

A new study has looked into the effects of psilocybin at a genetic and cellular level using fruit flies, because their neurotransmitter systems are similar to those of mammals. This has led to the discovery that one dose of the active compound produces a long-lasting, antidepressant-like effect in fruit flies. Psilocybin is the active compound found in magic mushrooms that produces changes in time perception, sensory perception, mood and sense of self. This can alter the way an individual experiences the world around them. Preliminary studies have shown that administering psilocybin in conjunction with psychotherapy may result in lasting improvements in major depressive disorder patients. Such studies shed light on how the different psychedelic compounds being championed by companies such as Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) work once they are introduced into the body for therapeutic purposes. The world will learn a lot more about these substances as the years go by and more studies are completed.

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.

Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.

The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source for those interested in ‎psychedelic culture, education, treatments, and more.

While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them under its big tent of resources and reach.

The Big Problems Delic Is Addressing

  • Fifty percent of Americans will meet the criteria for a mental health condition sometime in their lifetime. The FDA has approved psilocybin therapy as a breakthrough therapy for depression.
  • Every 40 seconds, someone in the world commits suicide. Ketamine has been shown to decrease thoughts of suicide significantly. In 2019, the FDA approved esketamine as a fast-acting antidepressant.
  • Traditional palliative care methods do not eradicate end-of-life (EOL) anxiety. LSD and psilocybin have been shown to reduce EOL anxiety for terminally ill patients. Eighty percent of terminally ill patients with psilocybin sessions experienced significant reductions in depression and anxiety.
  • Approximately 50 million people in the U.S. are addicted to some tobacco product. Research shows that psilocybin is helping people quit smoking.

The Delic Ecosystem

The Delic Ecosystem covers three main areas: media, health, and science. The media focus is educating and motivating the masses through a variety of digital platforms, like Delic’s Reality Sandwich digital magazine, a free public education platform providing psychedelic guides, news and ‎culture (1.4+ million page views in 2020 and 54k social media followers across all platforms); Meet Delic, the first-ever psychedelic wellness summit and the premier psychedelic wellness event based in Las Vegas (over 2,000 live attendees and 5,000+ email subscribers); and Delic Radio (over 43 episodes and 100k total streams). Delic has also been featured in numerous media outlets like Forbes, NBC News, The Joe Rogan Experience, Daily Beast, High Times, and The Dr. Drew Podcast.

The focus of Delic’s health operations is the most accessible psychedelic treatments that can help billions of people live happier lives. Delic does this through one of the largest ketamine clinic chains in the country, Ketamine Infusion Centers (KICs), a limited liability corporation formed under the laws of Arizona that runs three ketamine clinics located in Bakersfield, California, and Phoenix, Arizona. Its management team has over 15 years of experience in the clinic and medical space, scaling and operating over 20 clinics, with a plan to open 10 more clinics in the next 18 months. Together, these clinics have overseen 4,000+ treatments delivered to date.

The focus of Delic’s science operations is developing IP and advanced extraction and testing facilities that are the backbone of the legal market. Delic carries this out through Delic Labs, a licensed cannabis and psilocybin research laboratory based in Vancouver. It’s the only entity licensed by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.

Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. Health Canada gave it a Section 56 Exemption to work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.

Latest Acquisition – Homestead Book Company

On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company. Homestead is a legacy counterculture distributor of psychedelic media. It’s also the creator of one of the first self-contained psilocybin mushroom grow kits.

The acquisition of Homestead is an exciting one, as it shows how Delic is increasing accessibility to this nascent industry within regulated jurisdictions. Homestead has sold tens of thousands of mushroom kits globally and was one of the earliest distributors for High Times and many other counterculture publications.

The Homestead acquisition allows Delic to increase its product offerings on its website, Reality Sandwich, which recently hit a record for average monthly traffic of over 200,000 unique visitors and over 2.6 million active readers in 2020.

Market Outlook

The psychedelic renaissance is here. Just in time to help address the global mental health crises, plant medicines have the potential to help billions of people live happier lives. Thanks to university-led and FDA-approved studies, North America is leading the way in advancing an industry as psychedelics are becoming accepted globally for therapeutic, medical, and recreational use. Here are some statistics:

  • 32 million people in the U.S. have used psychedelics at least once
  • 17% of all American adults between 21 and 64 have used psychedelics at least once
  • $500 billion is spent in the U.S. every year on prescription drugs
  • $238 billion is spent in the U.S. every year on mental health treatments and ancillary services
  • The anxiety disorder and depression treatment market is estimated at $16 billion
  • $187.8 billion was spent in 2013 on mental health and substance abuse disorders

Management Team

Delic Co-Founder and CCO Jackee Stang was an executive at High Times, a leading counterculture publication that became the voice for the cannabis industry. The monthly magazine had a circulation of over 500,000 copies per issue. Its website attracted 500,000 to five million users each month by 2014.

Likewise, company Co-Founder and CEO Matt Stang was a previous owner and operator of High Times, a position from which he played an instrumental in legalizing cannabis in multiple states and launched the Cannabis Cup in America. After interacting with the cannabis community for two decades, he helped found Delic in 2019 as one of the first psychedelic corporations. He shapes the company’s vision and path using his expertise in branding, marketing, business development, and product viability.

Delic’s VP of Business Development, John Coleman, Ph.D., is a former president of Anandia Labs, a biotech company focused on genetics and analytics. Having experience in both science and business, Dr. Coleman is well-equipped to lead Delic’s business development efforts as it strives to enter new vertical markets.

Zak Garcia is the company’s Chief Marketing Officer. He was the former CMO of Bulletproof Inc., maker of the well-known Bulletproof Coffee brand. Mr. Garcia is a marketing and leadership strategist who helped grow Bulletproof Coffee to over $250 million in revenue.

Delic Holdings Corp. (DELCF), closed Tuesday's trading session at $0.0464, off by 5.5951%, on 171,069 volume. The average volume for the last 3 months is 171,069 and the stock's 52-week low/high is $0.03/$0.315.

Recent News

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF)

The QualityStocks Daily Newsletter would like to spotlight Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF).

Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) is a SaaS technology company focused on developing and licensing digital content for the growing global iGaming market. The company provides a multi-tenant gateway that allows online operators the ability to offer their customers innovative iGaming software solutions. Its current software platform includes Live Dealer Casino, E-Table Games and Daily Fantasy Sports. Seamless integration at the operator level allows customer access without requiring the sharing of any sensitive customer data. Playgon games run on any browser and any device as fast and secure as a native app, without requiring any app store download. All that’s needed is a stable internet connection. The gaming experience is identical across all mobile devices. As a true business-to-business digital content provider, the company’s products are scalable turnkey solutions for online casinos, sportsbook operators, location-based operators, media groups, and big database companies.

Playgon’s proprietary technology provides digital games for online gambling sites and mobile device apps, with the company licensing its mobile live-dealer technology to online gaming operators worldwide. Playgon combines high definition live streaming dealers with state-of-the-art augmented reality betting to provide the most authentic casino experience, live from Las Vegas. Playgon’s mobile platform features popular table games, all optimized for one-handed play on mobile devices.

The COVID-19 pandemic has accelerated an already existing shift away from location-based casinos to online gambling. At the same time, the proliferation of mobile devices has provided players with new access to betting. A younger, tech-savvy consumer demographic is driving adoption of digital gaming globally. To meet this demand, Playgon has launched a studio with 10 gaming tables from which its live dealer streaming video originates. The company’s platform is live with multiple online casino operators through four aggregator clients in South Africa and Europe, and commitments are coming in from more.

Playgon plans to expand the studio to 25 tables in the near term and is working to establish a U.S. strategy. The company will continue to expand licensing of its live dealer games to iGaming operators worldwide under a SaaS license agreement. As a B2B software supplier, Playgon avoids player acquisition costs.

Games

Live Dealer Casino

Playgon offers the first and only Live Dealer Casino streaming live from Las Vegas. The company brings cutting-edge handheld features and functionality to the mobile generation of gaming enthusiasts who demand a world-class gaming experience on all devices. Playgon’s Blackjack delivers the look and feel of location-based casino tables with features providing players with the most unique user experience. The company’s true-to-life Roulette offers players a clear and uninterrupted view of the dealer, wheel, ball, bets, results, trends and statistics. Players can strategize, place multiple bets, track results and review trends without ever losing focus of the game.

Playgon’s traditional Baccarat and proprietary Tiger Bonus Baccarat™ prove their worth by not only recognizing the need for a prominent product, but by adding elements which separate them from the pack without removing their authenticity. The games mix advances in technology with the traditional game attributes that have resonated and captivated players for hundreds of years.

eTable Games

To lead the rise of mobile-first gaming, Playgon developed a user experience perfected for one-handed play. Providing this next evolution in gaming technology ensures the company’s client operators loyalty from existing customers and is a powerful strategy to attract and retain new players. Playgon’s VEGAS LOUNGE™ brings together an innovative mix of games, technology and gameplay that offers players an authentic experience and real Las Vegas casino fun every time, everywhere.

Daily Fantasy Sports

Playgon’s Daily Fantasy Sports (DFS) are a subset of fantasy sport games which typically target a younger demographic. DFS provides iGaming operators a turnkey fantasy sports platform that can quickly go to market, integrate with the operator’s existing operations and services, and be customized to match and enhance the operator’s brand. The platform is mobile and desktop friendly, built for regulated market environments, and allows operators to monetize users through a network of shared liquidity.

Market Outlook

Online casinos and sports betting sites/apps are increasingly adding market share to traditional location-based casinos. This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, as well as tech like digital wallets and digital gameplay that underpins Playgon Games. The company has been described as “Netflix + Vegas, all in one.”

The online gambling market is slated to reach a value of $127.3 billion by 2027, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25 percent year over year. The current global online Live Casino TAM is estimated at about $6 billion annually, and revenue is forecast to reach more than $8 billion by 2023 and more than $13 billion by 2027.

Management Team

Darcy Krogh is CEO of Playgon Games. He is a veteran of the iGaming industry with over 20 years of experience. In 1999, he co-founded Chartwell Technology Inc., which pioneered the development of browser-based digital content for the iGaming industry. After that company was sold to Amaya Gaming Group, he served as VP Business Development with Amaya. In 2016, he started Playgon Games (formally Global Daily Fantasy Sports Inc.) as President and CEO. His experience in the online gaming industry includes sales and marketing, relationship management, corporate finance, M&A, and strategic corporate development.

Guido Ganschow is President of Playgon Interactive. He has more than 12 years of experience in creating real-time Live Dealer technology and platforms and was the co-founder and Creative Director for a Macau-based casino consortium. Between 2008 and 2014, he successfully created and established Live Dealer platform businesses in Asia and Europe, and executed commercial partnerships, sales, and integration of the Live Dealer solution with major global gaming brands, including Ho Gaming Group, Chartwell Technology and Amaya Gaming Group.

Steve Baker is COO of Playgon. He is a former VP Operations for Shaw Communications, where he was directly involved in video streaming, home entertainment, new products, sales and M&A. He oversaw revenue growth from $300 million to $2.8 billion and employee growth from 350 to 13,000. He has broad experience and a proven record in development and implementation of cost effective and efficient growth strategies transitioning businesses from development to operations.

Harry Nijjar is CFO of Playgon Games. He is currently a Managing Director with Malaspina Consultants Inc. and provides CFO and strategic financial advisory services to his clients across many industries. This experience has allowed him to help his clients successfully navigate the regulatory and financial environments within which they operate. Mr. Nijjar holds a CPA-CMA designation from the Chartered Professional Accountants of British Columbia.

Playgon Games Inc. (PLGNF), closed Tuesday's trading session at $0.04, off by 18.0328%, on 114,602 volume. The average volume for the last 3 months is 114,602 and the stock's 52-week low/high is $0.04/$0.406.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.